Effects of Bisphosphonate on the Expression of Matrix Enzymes during Endochondral Ossification
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Bisphosphonates have been reported to have chondroprotective activities in addition to its original functions. However, mechanisms for these just began to be elucidated. Under the hypothesis that bisphosphonates may regulate expression and activities of matrix enzymes during degradation of cartilage for bone formation, we administrated an alendronate (1 mg/kg) to newborn rats subcutaneously once a day for 4, 7, and 10 days. To identify the effects of alendronate on cartilage, thickness of cartilage layer was measured by histomorphometry on the proximal epiphysis of tibia. Immunofluorescence staining and RT-PCR were performed to investigate the expressions of matrix enzymes in both in vitro and in vivo. MTS assay revealed that at 10-3 M in concentration, alendronate significantly reduced viability of chondrocytes. The mRNA expressions of MMP-1, MMP-9, EMMPRIN, and TIMP-3 in primary chondrocytes were decreased by the alendronate treatment. Interestingly, TIMP-1 mRNA expression was significantly increased, whereas a constitutive form, TIMP-2 was relatively unchanged by the treatment. The thickness of proliferating layer at postnatal day 7 was not significantly different, whereas thickness of hypertrophied layer was significantly thicker in the alendronate group than in the control (p<0.01). Immunofluorescence demonstrated that the expressions of MMP- 9, TIMP-2 and -3 were reduced, whereas TIMP-1 expression was increased by the alendronate administration. These results suggest that the alendronate have chondroprotective properties by down-regulation of MMPs and up-regulation of TIMPs during endochondral ossification.
Abstract
Bisphosphonates have been reported to have chondroprotective activities in addition to its original functions. However, mechanisms for these just began to be elucidated. Under the hypothesis that bisphosphonates may regulate expression and activities of matrix enzymes during degradation of cartilage for bone formation, we administrated an alendronate (1 mg/kg) to newborn rats subcutaneously once a day for 4, 7, and 10 days. To identify the effects of alendronate on cartilage, thickness of cartilage layer was measured by histomorphometry on the proximal epiphysis of tibia. Immunofluorescence staining and RT-PCR were performed to investigate the expressions of matrix enzymes in both in vitro and in vivo. MTS assay revealed that at 10-3 M in concentration, alendronate significantly reduced viability of chondrocytes. The mRNA expressions of MMP-1, MMP-9, EMMPRIN, and TIMP-3 in primary chondrocytes were decreased by the alendronate treatment. Interestingly, TIMP-1 mRNA expression was significantly increased, whereas a constitutive form, TIMP-2 was relatively unchanged by the treatment. The thickness of proliferating layer at postnatal day 7 was not significantly different, whereas thickness of hypertrophied layer was significantly thicker in the alendronate group than in the control (p<0.01). Immunofluorescence demonstrated that the expressions of MMP- 9, TIMP-2 and -3 were reduced, whereas TIMP-1 expression was increased by the alendronate administration. These results suggest that the alendronate have chondroprotective properties by down-regulation of MMPs and up-regulation of TIMPs during endochondral ossification.
참고문헌 (30)
- Fleisch H, "Bisphosphonates : Mechanisms of action", Endocr Rev, 19, pp.80~100 (1998)
- Reinholz GG., "Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts", Cancer Res, 60, pp.6001~6007 (2000)
- review : Bisphosphonates and osteonecrosis of the jaws, "Ann Intern Med", 2006, 753~761
- Hillner BE., "American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer", J Clin Oncol, 21, pp.4042~4057 (2003)
- Clezardin P, "The antitumor potential of bisphosphonates", Semin Oncol, 29, pp.33~42 (2002)
- Palmieri C., "Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma : A mixed-treatment meta-analysis", Clin Cancer Res, 19, pp.6863~6872 (2013)
- Altundal H., "The effect of alendronate on resorption of the alveolar bone following tooth extraction", Int J Oral Maxillofac Surg, 33, pp.286~293 (2004)
- Bradaschia-Correa V., "Reduced rankl expression impedes osteoclast activation and tooth eruption in alendronate-treated rats", Cell Tissue Res, 353, pp.79~86 (2013)
- Zhao H., "The protective effects of incadronate on inflammation and joint destruction in established rat adjuvant arthritis", Rheumatol Int, 26, pp.732~740 (2006)
- Strassle BW., "Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease", Osteoarthritis Cartilage, 18, pp.1319~1328 (2010)
- Mohan G., "Pre-emptive, early, and delayed alendronate treatment in a rat model of knee osteoarthritis : Effect on subchondral trabecular bone microarchitecture and cartilage degradation of the tibia, bone", cartilage turnover, and joint discomfort, 2013, pp.21, 1595~1604
- Zhu S., "Alendronate protects against articular cartilage erosion by inhibiting subchondral bone loss in ovariectomized rats", Bone, 53, pp.340~349 (2013)
- Reid IR., "A single infusion of zoledronic acid produces sustained remissions in paget disease: Data to 6.5 years", J Bone Miner Res, 26, pp.2261~2270 (2011)
- Seo SK., "Changes in serum levels of cartilage oligomeric matrix protein after estrogen and alendronate therapy in postmenopausal women", Gynecol Obstet Invest, 74, pp.143~150 (2012)
- Paiva KB., "Bone tissue remodeling and development : Focus on matrix metalloproteinase functions", Arch Biochem Biophys, 561, pp.74~87 (2014)
- Nagase H., "Structure and function of matrix metalloproteinases and timps", Cardiovasc Res, 69, pp.562~573 (2006)
- Kaushik DK, "Emmprin, an upstream regulator of mmps, in cns biology", Matrix Biol, 44(46c), pp.138~146 (2015)
- Gao Y., "The ecm-cell interaction of cartilage extracellular matrix on chondrocytes", Biomed Res Int, 2014, pp.1~8 (2014)
- Pelletier JP., "Carprofen simultaneously reduces progression of morphological changes in cartilage and subchondral bone in experimental dog osteoarthritis", J Rheumatol, 27, pp.2893~2902 (2000)
- Pap T, "Cartilage damage in osteoarthritis and rheumatoid arthritis-two unequal siblings", Nat Rev Rheumatol (2015)[DOI]
- Murphy G., "What are the roles of metalloproteinases in cartilage and bone damage?", Ann Rheum Dis, 64, pp.44~47 (2005)
- Davidson RK, "Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage", Arthritis Res Ther, 8, pp.R124~ (2006)
- Funck-Brentano T, "Targeting bone alleviates osteoarthritis in osteopenic mice and modulates cartilage catabolism", PLoS One, 7, pp.e33543~ (2012)
- Dearmin MG., "Chondroprotective effects of zoledronic acid on articular cartilage in dogs with experimentally induced osteoarthritis", Am J Vet Res, 75, pp.329~337 (2014)
- Rogers TL., "Tumour macrophages as potential targets of bisphosphonates", J Transl Med, 9, pp.177~194 (2011)
- Vu TH., "Mmp-9", gelatinase b is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes, 1998, pp.93, 411~422
- Murphy G, "Tissue inhibitors of metalloproteinases", Genome Biol, 12, pp.233~240 (2011)
- Leco KJ., "Murine tissue inhibitor of metalloproteinases-4(timp-4) : Cdna isolation and expression in adult mouse tissues", FEBS Lett, 401, pp.213~217 (1997)
- Stetler-Stevenson WG., "Timp-2 : An endogenous inhibitor of angiogenesis", Trends Mol Med, 11, pp.97~103 (2005)
- Kashiwagi M., "Timp-3 is a potent inhibitor of aggrecanase 1(adam-ts4)and aggrecanase 2(adam-ts5)", J Biol Chem, 276, pp.12501~12504 (2001)